written by reader ET-73 ?? (Cancer Teaser, Michael Robinson, Nova-X Report)

By mrproby, August 26, 2016

What is Et-73, and what small biotech company is about to go IPO, that controls it?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

40 Comments
Inline Feedbacks
View all comments
Travis Johnson, Stock Gumshoe
August 29, 2016 12:15 pm

We had three different discussions running about this teaser pitch, I’ve collated them all into this one place. It was also discussed quite actively when it was pitched as ET-743 by the same publishers back in February of this year here.

👍 18054
Miceal
Miceal
August 30, 2016 5:17 pm

PharmaMar (Madrid) some facts:
Its oncology portfolio has been validated through global partnerships, eg J&J in the US and Taiho in Japan (for Yondelis) and Chugai in certain EU countries (for Aplidin).

It has a pipeline of cancer drugs with strategic partners, e.g. Yondelis for soft tissue sarcoma in Japan and the US with profit growth from 2017. The 420-patient CORAIL Phase III trial of PM1183 in platinum-resistant ovarian cancer was cleared to continue in August after an interim futility analysis on the first 210 patients. Another pivotal study of PM1183 was initiated in August – the 600-patient Phase III ATLANTIS study will evaluate PM1183 in combination with doxorubicin in patients with small cell lung cancer. The Phase III trial of Aplidin in multiple myeloma reported positive results in March, while a pivotal study of Aplidin in angioimmunoblastic T-cell lymphoma was initiated in June.

There has been no recent re-affirmation by the company re the US IPO.

Add a Topic
5350
Add a Topic
1029
Add a Topic
3397
👍 312
Ben
Member
Ben